ADVA
12.3.2020 09:02:07 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched a whole new way for communication service providers (CSPs) to drive more revenue from their already deployed fiber networks. With spectrum as a service , CSPs can now slice the optical spectrum in their fiber infrastructure, just like radio spectrum in 5G networks. They can then sell different frequency blocks to different customers, enabling them to fully harness the untapped value in their networks. Powered by ADVA’s FSP 3000 open line system (OLS), spectrum as a service is an entirely new approach for CSPs to utilize vast amounts of unused spectrum. By leveraging ADVA’s coherent optics, programmable flexgrid technology and intelligent network control, CSPs can start selling fully assured and differentiated optical spectrum services to their customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200312005038/en/
“Today we’re introducing a new way for CSPs to tackle skyrocketing data demand and diminishing margins. Optical spectrum in fiber networks can now be sliced and offered as differentiated services to multiple end users. This gives CSPs a completely fresh business case and a brand new area for revenue growth,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Our unique open line system is the key to realizing the full benefits of the spectrum-as-a-service approach. Its spectrum gateway functionality and advanced optical layer control empower CSPs to elastically allocate optical spectrum to services and deliver virtually unlimited capacity. What’s more, with optical spectrum services, CSPs can put their end customers in control like never before.”
The ADVA FSP 3000 OLS provides the optimum platform for spectrum-as-a-service offerings. It creates an open and scalable optical layer ready to accommodate evolving demand and the latest innovation. With a modular design as well as multiple multiplexer and amplifier options, it's engineered to meet the specific requirements of modern metro, core and DCI applications. The ADVA FSP 3000 OLS removes the limits of the traditional fixed channel grid systems so that unused spectrum can be put to work. This approach also enables operators to take advantage of flexible resource utilization and future-proof their networks by avoiding unnecessary O/E/O conversions.
“Up until now, CSPs have been unable to monetize the vast amounts of unused spectrum in their networks. But thanks to advances in coherent optics, programmable flexgrid technology and intelligent network control, spectrum as a service is now a real and affordable option. CSPs can use the approach to unleash the full value of their fiber assets,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Following multiple spectrum-as-a-service proof-of-concepts involving several partners and spanning different network domains, we're now removing the limits on fiber capacity for CSPs across the world. With this launch, we're unlocking the potential of today's fiber infrastructure and ushering in a new age of flexible, future-proof growth.”
Watch this video for more information on ADVA’s spectrum-as-a-service solution: https://youtu.be/FBCuuvYWN4A .
Further details are also available in these slides: https://adva.li/spectrum-as-a-service-slides .
Learn more about ADVA’s FSP 3000 open line system in this video: https://youtu.be/E_P8_ypxR1w .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005038/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom